Keywords: Mylan, Novartis, Vivelle-Dot, Menopause, Pay-for delay, Impax Labs, Fentora, Cephalon, CIMA Labs, Cancer pain

Mylan settles with Novartis over Vivelle-Dot; Impax files for generic Fentora

Article | 21 November 2011

Print This

US generics drugmaker Mylan (Nasdaq: MYL) says it has settled a patent litigation law suit with the US subsidiary of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in